Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR17 | Q13304 | 1/20 | 0.43 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.38 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4568440 | 0.91 | KDM4E (0.41) | GPR17PTGS2MTNR1AMTNR1BMRGPRX4 | |
| SCHEMBL4568584 | 0.86 | GPR17 (0.43) | GPR17PTGS2MTNR1AMTNR1BMRGPRX4 | |
| SCHEMBL4568558 | 0.86 | GPR17 (0.45) | GPR17PTGER1PTGS2MTNR1AMTNR1B | |
| SCHEMBL15975115 | 0.86 | MTNR1A (0.37) | GPR17PTGS2MTNR1AMTNR1BBRD4 | |
| SCHEMBL4568595 | 0.84 | PTGER1 (0.46) | PTGER1MRGPRX4 | |
| SCHEMBL4568553 | 0.83 | GPR17 (0.43) | GPR17PTGER1PTGS2MRGPRX4DYRK1A | |
| SCHEMBL3704461 | 0.83 | GPR17 (0.44) | GPR17MTNR1AMTNR1BALDH1A1HPGD | |
| SCHEMBL4568213 | 0.83 | GPR17 (0.46) | GPR17PTGER1PTGS2MRGPRX4DYRK1A | |
| SCHEMBL4568567 | 0.82 | GPR17 (0.43) | GPR17PTGER1PTGS2MRGPRX4DYRK1A | |
| SCHEMBL3702535 | 0.82 | TUBB4A (0.48) | GPR17MTNR1AMTNR1BALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2474530-B1 | INDOLE DERIVATIVE AND PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL (JP) | 2014-09-03 | — | — | EP | disclosed |
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | PTGER1, CYSLTR1, LTB4R | GPR17 59/4885PTGER1 1/4885PTGS2 257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.